$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Chemotherapy plus durvalumab, bevacizumab, and olaparib fails to provide OS benefit in newly diagnosed non-tBRCA mutated ovarian cancer
2026-02-01 22:25:32
Check Details
What are the differences in efficacy and uses between Valganciclovir and ganciclovir?
2026-02-01 22:25:32
Check Details
Clinical effects of axitinib (Inlida) in the treatment of renal cancer and real feedback from patients
2026-02-01 22:25:32
Check Details
Detailed description of the recommended starting dose and adjustment principles of Trametinib (Megenin)
2026-02-01 22:25:32
Check Details
Is zolbetuximab a self-paid drug or a medically insured drug?
2026-02-01 22:25:32
Check Details
Can 0.01% atropine sulfate eye drops (EIKANCE) be used by children for a long time?
2026-02-01 22:25:32
Check Details
Reasons and Solutions for Platelet Failure to Elevate with Avatrombopag (Sucoxin)
2026-02-01 22:25:32
Check Details
Analysis of the efficacy of giritinib (segatan) in patients with acute monocytic leukemia
2026-02-01 22:25:32
Check Details
The drug name of Margetuximab marketed in China
2026-02-01 22:25:32
Check Details
Possible reasons and solutions for ineffectiveness of taking Osimertinib (Tagressa)
2026-02-01 22:25:32
Check Details
What foods should not be consumed while taking Eltrombopag (Revlan)?
2026-02-01 22:25:32
Check Details
How will the effect of combining ivonib/Tosuvo with targeted drugs be improved?
2026-02-01 22:25:32
Check Details
1
2
...
2238
2239
2240
2241
2242
2243
2244
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Lapatinib Side Effects: Managing Diarrhea, Skin Reactions, and Liver Function Changes
2
Trelagliptin: A Once-Weekly Long-Acting Oral DPP-4 Inhibitor
3
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
4
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
5
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
6
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
7
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
8
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
9
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
10
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
11
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
12
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments